Edition:
India

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

14.20USD
23 Feb 2018
Change (% chg)

$0.13 (+0.92%)
Prev Close
$14.07
Open
$14.11
Day's High
$14.52
Day's Low
$13.91
Volume
32,164
Avg. Vol
89,213
52-wk High
$26.74
52-wk Low
$11.81

Select another date:

Sat, Jan 13 2018

BRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals

* ORBIMED ADVISORS LLC REPORTS ABOUT 11 PERCENT PASSIVE STAKE IN KALA PHARMACEUTICALS INC AS OF JAN 10 Source text: (http://bit.ly/2DaEc0a) Further company coverage:

Future of Kala Pharma's dry eye drug uncertain after mixed results

Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc's drug to provide temporary relief from dry eye disease cast doubt on the drug's path forward and sent shares down 16 percent in early trading on Friday.

UPDATE 2-Future of Kala Pharma's dry eye drug uncertain after mixed results

* Peak sales could hit $1.9 bln in 2027 - analyst (Recasts lede, updates shares, adds analyst comments)

REFILE-Kala Pharma posts mixed results from dry eye disease drug studies

Jan 5 Kala Pharmaceuticals Inc on Friday reported mixed results from two late-stage trials testing its drug to provide temporary relief from the signs and symptoms of dry eye disease.

BRIEF-Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA

* KALA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION FOR INVELTYSTM (KPI-121 1%) HAS BEEN ACCEPTED FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION

BRIEF-Kala Pharmaceuticals Announces Topline Results For Two Phase 3 Trials Of Kpi-121

* KALA PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FOR TWO PHASE 3 TRIALS (STRIDE 1 AND STRIDE 2) OF KPI-121 0.25% IN DRY EYE DISEASE

BRIEF-Kala Pharmaceuticals reports Q3 loss per share $0.56

* Kala Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-Kala Pharmaceuticals submits new drug application for Inveltystm

* Kala pharmaceuticals submits new drug application to U.S. Food and Drug Administration for Inveltystm (KPI-121 1 pct) Source text for Eikon: Further company coverage:

Select another date: